The fundamental difference between MDL (multidistrict litigation) and a class action comes down to individual control versus collective representation. In an MDL, each plaintiff maintains their own separate lawsuit with their own attorney and retains the right to accept or reject settlement offers independently. In a class action, plaintiffs merge into a single lawsuit where one or more representative plaintiffs make decisions on behalf of everyone, and the outcome binds all class members unless they formally opt out. This distinction matters enormously when you’re deciding how to pursue a legal claim””particularly in cases involving defective products, pharmaceutical injuries, or corporate misconduct affecting thousands of people.
Consider the Roundup herbicide litigation. Thousands of plaintiffs alleging the weedkiller caused their cancer have individual cases consolidated in MDL-2741 for pretrial efficiency, but each person’s settlement depends on factors specific to their situation””their diagnosis, their exposure history, their medical costs. Had this been structured as a class action instead, every plaintiff would receive the same predetermined compensation regardless of whether they developed non-Hodgkin lymphoma after twenty years of professional landscaping or after occasional home garden use. This article breaks down the structural, legal, and practical differences between these two litigation mechanisms, examines current statistics showing MDLs now dominate federal civil caseloads, and explains what recent rule changes mean for plaintiffs navigating either path.
Table of Contents
- How Does MDL Differ From Class Action Litigation in Structure and Purpose?
- Why Individual Control Matters in Mass Litigation
- The Scale of MDL Litigation in Federal Courts
- When Should You Pursue MDL Versus Class Action?
- Limitations and Risks in Both Approaches
- How Recent Rule Changes Affect MDL Proceedings
- What These Litigation Tools Mean for Future Mass Harm Cases
- Conclusion
How Does MDL Differ From Class Action Litigation in Structure and Purpose?
MDL and class action lawsuits solve the same basic problem””how courts handle large numbers of similar claims efficiently””but they approach it from opposite directions. An MDL consolidates separate lawsuits only for pretrial purposes before a single federal judge. Discovery, motions, and early rulings happen in one courtroom, but each case retains its individual identity. After pretrial proceedings conclude, cases that don’t settle can be sent back (remanded) to their original courts for trial. Class actions take the opposite approach: multiple plaintiffs merge into one lawsuit from the start, with representative plaintiffs standing in for an entire group sharing common legal claims.
The jurisdictional difference is also significant. MDLs exist only in federal court, overseen by the United States Judicial Panel on multidistrict Litigation (JPML)””a body of seven circuit and district judges selected by the Chief Justice. Class actions can be filed in either federal or state court, governed by Rule 23 of the Federal Rules of Civil Procedure in federal proceedings. This structural distinction creates different experiences for plaintiffs. Someone whose case ends up in an MDL still has their own attorney, their own case file, and their own voice in whether to settle. Someone who becomes part of a class action””often without taking any action at all””is represented by class counsel and bound by whatever the court approves unless they take affirmative steps to opt out.
Why Individual Control Matters in Mass Litigation
The question of individual control isn’t abstract””it directly affects how much money injured parties receive and whether they have any say in the outcome. In an MDL, each plaintiff retains their own attorney who advocates specifically for them. Settlement negotiations often use “settlement grids” or tiered structures that account for injury severity, documented medical expenses, strength of evidence, and other individualized factors. A plaintiff who suffered catastrophic injuries may receive a substantially different amount than someone with less severe harm, even when both cases involve the same defendant and the same defective product. Class actions work differently.
Any settlement or judgment applies uniformly to all class members. Courts must approve these settlements to ensure fairness to the entire class, but that approval process focuses on whether the deal is reasonable for the group as a whole””not whether it adequately compensates any particular individual. Someone with unusually severe injuries or unusually strong evidence has no mechanism to demand more; their recovery is determined by their membership in the class, not by their individual circumstances. However, this uniformity has advantages in certain situations. When individual damages are small””think a company overcharging customers by a few dollars each, or a data breach exposing personal information without causing direct financial loss””class actions make litigation feasible where individual lawsuits would be impractical. No attorney would take a case worth $50 in damages, but a class action representing millions of people with $50 claims creates meaningful accountability.
The Scale of MDL Litigation in Federal Courts
MDL has become the dominant form of federal civil litigation, a development that would have seemed unlikely when Congress created the mechanism in 1968. As of fiscal year 2024, MDL cases constituted 67.8 percent of the pending federal civil caseload””up from 29 percent just thirteen years earlier. Of 481,533 cases pending in federal courts, 326,539 cases were pending in 1,846 MDLs. The 2018 milestone marked a turning point: for the first time, more than half (51.9 percent) of all federal civil cases were centralized into MDLs, with 156,511 cases in 248 MDLs. Products liability drives this dominance.
By category, products liability accounts for 32.9 percent of total MDLs, followed by antitrust at 24.1 percent and sales practices at 12.1 percent. But the raw numbers tell an even more dramatic story: products liability accounts for 91 percent of the total civil cases within MDLs. This concentration reflects the nature of pharmaceutical and medical device litigation, where a single defective product can injure tens of thousands of people across the country, each with their own unique medical history and damages profile. The JPML publishes monthly reports tracking these figures. Major pending MDLs as of early 2026 include roundup Products Liability (MDL-2741), National Prescription Opiate Litigation (MDL-2804), GLP-1 RAs Products Liability (MDL-3094), Uber Passenger Sexual Assault (MDL-3084), Social Media Adolescent Addiction (MDL-3047), 23andMe Data Breach (MDL-3098), and Baby Food Products Liability (MDL-3101).
When Should You Pursue MDL Versus Class Action?
The choice between MDL and class action””to the extent plaintiffs have a choice””depends largely on the nature of the alleged harm. MDL tends to work better when damages vary significantly among plaintiffs. Personal injury cases involving defective drugs or medical devices exemplify this: one plaintiff may have suffered organ failure requiring a transplant while another experienced manageable side effects requiring medication adjustments. Treating these claims identically would be unjust to the more severely injured party. Class actions work better when the legal and factual questions are genuinely common and damages are relatively uniform.
Securities fraud cases often fit this model””every shareholder who bought stock during the relevant period overpaid by the same percentage. Consumer protection cases where a company charged illegal fees or made false advertising claims to all customers similarly present common questions suitable for class treatment. The tradeoff involves efficiency versus individualization. Class actions resolve everything at once, for everyone, with a single judgment or settlement. MDLs achieve pretrial efficiency but preserve individual resolution””which also means they can take longer, cost more in aggregate legal fees, and leave some plaintiffs waiting years while bellwether trials establish settlement values.
Limitations and Risks in Both Approaches
Neither MDL nor class action guarantees a favorable outcome, and both carry risks that plaintiffs should understand before proceeding. In MDLs, the consolidation for pretrial purposes creates efficiency, but it can also create delays. Cases may sit for years while the court works through discovery disputes, motions for summary judgment, and bellwether trials designed to establish what typical verdicts might look like. If your case is one of thousands, you may feel lost in the crowd despite technically maintaining individual status. The settlement dynamics in MDL can also create pressure.
When defendants negotiate “global” settlements, there’s often implicit or explicit pressure on individual plaintiffs to participate even if the settlement undervalues their particular claims. Attorneys who have invested years in the MDL may encourage clients to accept offered amounts rather than risk remand to their original courts for expensive individual trials. Class actions carry different risks. If you’re a class member with unusually strong claims or severe injuries, you may be bound by a settlement that inadequately compensates you specifically. The opt-out window is typically limited and easy to miss. And class certification itself isn’t guaranteed””defendants frequently fight certification, and if a class gets decertified mid-litigation, plaintiffs may find themselves starting over.
How Recent Rule Changes Affect MDL Proceedings
The procedural landscape for MDL shifted meaningfully in late 2025. In April 2025, the U.S. Supreme Court transmitted new MDL rules to Congress, and Rule 16.1 went into effect on December 1, 2025.
These changes aim to standardize certain aspects of MDL practice that previously varied widely between transferee judges””the judges who receive consolidated cases from the JPML. The new rules address issues like initial case management, coordination between counsel, and transparency in how MDLs are administered. For plaintiffs, this means more predictability in how their cases will be handled regardless of which judge receives the MDL. The JPML continues to meet regularly to consider new consolidation requests and manage existing MDLs; the next hearing is scheduled for January 29, 2026, in San Diego, California.
What These Litigation Tools Mean for Future Mass Harm Cases
The continuing growth of MDL reflects a broader reality: mass harm from defective products, corporate misconduct, and institutional failures isn’t decreasing. Emerging litigation areas like social media addiction, GLP-1 weight loss drugs, and data breaches show how new technologies and industries create new categories of mass injury requiring collective legal response.
Both MDL and class action will remain essential tools. MDL’s dominance in federal courts””now representing over two-thirds of the civil caseload””suggests it will continue handling most large-scale personal injury matters. Class actions will likely remain the preferred vehicle for consumer protection, antitrust, and securities cases where uniform treatment of plaintiffs makes practical sense.
Conclusion
MDL and class action represent fundamentally different approaches to the same problem of judicial efficiency in mass litigation. MDL preserves individual plaintiff control, allows for individualized settlements based on specific injuries and circumstances, and exists exclusively in federal court under JPML oversight. Class actions consolidate plaintiffs into a single representative lawsuit, bind all class members to the outcome unless they opt out, and can proceed in either federal or state court.
For anyone facing potential involvement in either type of litigation, understanding these differences helps set realistic expectations. If you’re seriously injured by a defective product and your case joins an MDL, you retain meaningful control over your settlement decision. If you receive a class action notice in the mail, you need to decide whether the uniform recovery justifies staying in the class or whether opting out to pursue individual claims makes sense. Neither path is inherently better””the right choice depends on the nature of the harm, the uniformity of damages, and your tolerance for the time and uncertainty involved.